OBJECTIVE: To analyze the influence of HIV serostatus on mortality related to tuberculosis (TB) in the context of wide access to highly active antiretroviral therapy (HAART) in a middle-income country. METHODS: Prospective cohort study including patients who started antituberculous therapy between April 2000 and July 2005 at a referral center in Rio de Janeiro, Brazil. RESULTS: Two hundred seven patients were enrolled, 106 were seropositive for HIV. There were 21 TB-related deaths in HIV-positive subjects (24.7 deaths per 100 patient-years) and 2 (2.5 deaths per 100 patient-years) among HIV-negative patients (rate ratio = 9.76, P < 0.001). Among HIV-infected subjects, TB-related mortality tended to be lower in patients treated with HAART [hazard ratio (HR) = 0.58, P = 0.06]. However, mortality among patients treated with HAART was still significantly increased as compared with HIV-negative patients (HR = 6.6, P = 0.014). In a Cox regression model adjusted for disseminated TB (P = 0.04), and treatment with antituberculous regimens not containing rifampicin (P = 0.11), mortality was significantly higher among seropositive patients not on HAART compared with HIV-negative subjects (HR = 6.30, P = 0.024). Among subjects treated with HAART, there was a nonsignificant increase in mortality (rate ratio = 3.48, P = 0.14). CONCLUSIONS: HIV infection still has a substantial impact on TB-related mortality in the context of wide access to HAART in a middle-income country.
OBJECTIVE: To analyze the influence of HIV serostatus on mortality related to tuberculosis (TB) in the context of wide access to highly active antiretroviral therapy (HAART) in a middle-income country. METHODS: Prospective cohort study including patients who started antituberculous therapy between April 2000 and July 2005 at a referral center in Rio de Janeiro, Brazil. RESULTS: Two hundred seven patients were enrolled, 106 were seropositive for HIV. There were 21 TB-related deaths in HIV-positive subjects (24.7 deaths per 100 patient-years) and 2 (2.5 deaths per 100 patient-years) among HIV-negative patients (rate ratio = 9.76, P < 0.001). Among HIV-infected subjects, TB-related mortality tended to be lower in patients treated with HAART [hazard ratio (HR) = 0.58, P = 0.06]. However, mortality among patients treated with HAART was still significantly increased as compared with HIV-negative patients (HR = 6.6, P = 0.014). In a Cox regression model adjusted for disseminated TB (P = 0.04), and treatment with antituberculous regimens not containing rifampicin (P = 0.11), mortality was significantly higher among seropositive patients not on HAART compared with HIV-negative subjects (HR = 6.30, P = 0.024). Among subjects treated with HAART, there was a nonsignificant increase in mortality (rate ratio = 3.48, P = 0.14). CONCLUSIONS:HIV infection still has a substantial impact on TB-related mortality in the context of wide access to HAART in a middle-income country.
Authors: Philippe Glaziou; Katherine Floyd; Eline L Korenromp; Charalambos Sismanidis; Ana L Bierrenbach; Brian G Williams; Rifat Atun; Mario Raviglione Journal: Bull World Health Organ Date: 2011-05-31 Impact factor: 9.408
Authors: Lauren S Peetluk; Peter F Rebeiro; Marcelo Cordeiro-Santos; Afranio Kritski; Bruno B Andrade; Betina Durovni; Solange Calvacante; María B Arriaga; Megan M Turner; Marina C Figueiredo; Valeria C Rolla; Timothy R Sterling Journal: J Infect Dis Date: 2020-04-07 Impact factor: 5.226
Authors: André M Japiassú; Rodrigo T Amâncio; Emerson C Mesquita; Denise M Medeiros; Helena B Bernal; Estevão P Nunes; Paula M Luz; Beatriz Grinsztejn; Fernando A Bozza Journal: Crit Care Date: 2010-08-10 Impact factor: 9.097
Authors: Masja Straetemans; Ana L Bierrenbach; Nico Nagelkerke; Philippe Glaziou; Marieke J van der Werf Journal: PLoS One Date: 2010-12-30 Impact factor: 3.240
Authors: Amr S Albanna; Michael B Reed; Kimberley V Kotar; Ashley Fallow; Fiona A McIntosh; Marcel A Behr; Dick Menzies Journal: PLoS One Date: 2011-09-19 Impact factor: 3.240
Authors: Tatiana P da Silva; Carmem B W Giacoia-Gripp; Carolina A Schmaltz; Flavia M Sant Anna; Valeria Rolla; Mariza G Morgado Journal: PLoS One Date: 2013-06-19 Impact factor: 3.240